MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$6,704,138
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from registered direct ...
Share-based compensation expense
Decrease in prepaid expenses and...
Others
Negative Cash Flow Breakdown
Net loss
Decrease in accounts payable
Payment of issuance costs
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Loss on debt conversion with related party
-
0
0
-6,134,120
Net loss
-4,986,614
-3,780,449
-15,744,616
-14,732,305
Loss on foreign exchange
-5,860
-10,963
-15,241
-1,712
Loss on fixed asset disposal
-
-2,731
-
-
Amortization of loan costs
-
0
0
52,373
Depreciation
-
0
-32,215
34,278
Reduction in carrying amount of right-of-use asset
16,839
16,562
49,553
-
Acquisition of license for research and development
-
-121,000
12,030,667
-
Deferred sublease income
-38,911
-
-
-
Deferred tax expense
1,193
31,841
-1,436
190,691
Share-based compensation expense
449,419
157,860
48,281
149,501
Decrease in prepaid expenses and other current assets
-288,886
377,560
227,655
-396,528
Decrease in accounts payable
-589,511
118,965
86,734
-738,306
Increase (decrease) in accrued expenses and other liabilities
187,830
302,900
502,654
-197,264
Net cash used in operating activities
-4,587,187
-3,637,187
-3,272,792
-8,708,672
Proceeds from public offering of common stock, net of offering costs
-
4,252,245
-
-
Proceeds from loan with related party, net of fees
-
0
0
3,000,000
Proceeds from registered direct offering of common stock, net of offering costs
11,397,459
-4,165,879
0
4,252,245
Proceeds from the exercise of prefunded warrants
132
-
-
-
Payment of issuance costs
106,266
53,805
-
-
Net cash provided by financing activities
11,291,325
32,561
0
7,252,245
Net increase in cash
6,704,138
-3,604,626
-3,272,792
-1,456,427
Cash, beginning of period
6,524,744
10,126,710
14,847,949
-
Effect of foreign currency translation on cash
-1,043
2,660
7,980
-
Cash, end of period
13,227,839
6,524,744
10,126,710
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from registered
direct offering of...
$11,397,459
Proceeds from the
exercise of prefunded...
$132
Net cash provided by
financing activities
$11,291,325
Canceled cashflow
$106,266
Net increase in cash
$6,704,138
Canceled cashflow
$4,587,187
Payment of issuance
costs
$106,266
Share-based compensation
expense
$449,419
Decrease in prepaid
expenses and other...
-$288,886
Increase (decrease) in
accrued expenses and...
$187,830
Deferred sublease income
-$38,911
Reduction in carrying
amount of right-of-use...
$16,839
Loss on foreign
exchange
-$5,860
Deferred tax expense
$1,193
Net cash used in
operating activities
-$4,587,187
Canceled cashflow
$988,938
Net loss
-$4,986,614
Decrease in accounts
payable
-$589,511
Buy us a coffee
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)